Keros Therapeutics (KROS) Enterprise Value (2019 - 2025)

Keros Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$287.4 million in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value rose 48.67% year-over-year to -$287.4 million; the trailing twelve-month figure through Dec 2025 stood at -$287.4 million (up 48.67% YoY), and the FY2025 full-year result was -$287.4 million, up 48.67% from the prior year.
• Enterprise Value for Q4 2025 stood at -$287.4 million, up from -$693.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$215.6 million in Q2 2022, with the low at -$720.5 million in Q1 2025.
• Historically, Enterprise Value has averaged -$376.5 million across 5 years, with a median of -$305.0 million in 2023.
• Annual changes were most pronounced in 2021 — Enterprise Value plunged 368.11% — and 2025, when it soared 48.67%.
• Keros Therapeutics' Enterprise Value stood at -$230.0 million in 2021, then declined by 21.3% to -$279.0 million in 2022, then retreated by 18.67% to -$331.1 million in 2023, then sank by 69.09% to -$559.9 million in 2024, then soared by 48.67% to -$287.4 million in 2025.
• The last three Enterprise Value figures came in at -$287.4 million (Q4 2025), -$693.5 million (Q3 2025), and -$690.2 million (Q2 2025), per Business Quant data.